Education
About Us
Working with TipRanks
Follow Us
CAMP4 Therapeutics Corporation (CAMP)
NASDAQ:CAMP
CAMP Stock Chart & Stats
$6.75
-$0.13(-2.84%)
At close: 4:00 PM EST
$6.75
-$0.13(-2.84%)
Day’s Range― - ―
52-Week Range$1.31 - $7.79
Previous Close$4.45
Volume38.22K
Average Volume (3M)1.59M
Market Cap
$304.26M
Enterprise Value-$8.43M
Total Cash (Recent Filing)$75.25M
Total Debt (Recent Filing)$6.35M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
Mar 26, 2026EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding46,881,134
10 Day Avg. Volume141,089
30 Day Avg. Volume1,592,597
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.61
Price to Sales (P/S)156.16
P/FCF Ratio-2.21
Enterprise Value/Market Cap-0.03
Enterprise Value/Revenue-2.22
Enterprise Value/Gross Profit-2.49
Enterprise Value/Ebitda0.16
Forecast
1Y Price Target
$9.00Price Target Upside33.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe company has raised $50M in a private placement, providing a financial runway into 2027 and demonstrating investor confidence.
Research And DevelopmentCAMP4's proprietary RNA-based technology platform shows strong potential to target a wide spectrum of haploinsufficient diseases.
Strategic PartnershipsCAMP4 will have access to natural history data collected by SynGAP Research Fund and Children's Hospital of Philadelphia, supporting future clinical study enrollment.
Bears Say
Clinical Development RisksThe lead program, CMP-SYNGAP-01 for SYNGAP-related disorders, is in a very early stage with a long time horizon to patient level value creation.
Investment UncertaintyCAMP will not make any additional investment in the CMP-CPS-01 program and will explore partnership opportunities instead.
Market OutlookThere is no price target on CAMP shares, and the lead program's early stage contributes to the Neutral rating.
CAMP4 Therapeutics Corporation News
CAMP FAQ
What was CAMP4 Therapeutics Corporation’s price range in the past 12 months?
CAMP4 Therapeutics Corporation lowest stock price was $1.30 and its highest was $7.79 in the past 12 months.
What is CAMP4 Therapeutics Corporation’s market cap?
CAMP4 Therapeutics Corporation’s market cap is $304.26M.
When is CAMP4 Therapeutics Corporation’s upcoming earnings report date?
CAMP4 Therapeutics Corporation’s upcoming earnings report date is Mar 26, 2026 which is in 99 days.
How were CAMP4 Therapeutics Corporation’s earnings last quarter?
CAMP4 Therapeutics Corporation released its earnings results on Nov 20, 2025. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.478 by -$0.072.
Is CAMP4 Therapeutics Corporation overvalued?
According to Wall Street analysts CAMP4 Therapeutics Corporation’s price is currently Undervalued.
Does CAMP4 Therapeutics Corporation pay dividends?
CAMP4 Therapeutics Corporation does not currently pay dividends.
What is CAMP4 Therapeutics Corporation’s EPS estimate?
CAMP4 Therapeutics Corporation’s EPS estimate is -0.34.
How many shares outstanding does CAMP4 Therapeutics Corporation have?
CAMP4 Therapeutics Corporation has 46,881,134 shares outstanding.
What happened to CAMP4 Therapeutics Corporation’s price movement after its last earnings report?
CAMP4 Therapeutics Corporation reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.478. Following the earnings report the stock price went down -17.379%.
Which hedge fund is a major shareholder of CAMP4 Therapeutics Corporation?
Currently, no hedge funds are holding shares in CAMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CAMP4 Therapeutics Corporation Stock Smart Score
Company Description
CAMP4 Therapeutics Corporation
CAMP4 Therapeutics Corporation (CAMP) is a biotechnology company focused on harnessing the power of RNA biology to develop transformative therapies for patients with serious diseases. The company operates primarily in the biotechnology sector, with a strong emphasis on leveraging its proprietary CAMP4 platform, which utilizes advanced computational and experimental techniques to identify and develop novel therapeutic candidates. CAMP's core products and services include therapeutic programs targeting genetic disorders and other diseases, with a focus on RNA-targeted therapies that aim to modulate gene expression and restore normal cellular function.
CAMP Stock 12 Month Forecast
Average Price Target
$9.00
▲(33.33% Upside)
Technical Analysis
Relmada Therapeutics
―
Beyondspring
―
MiNK Therapeutics
―
Artiva Biotherapeutics, Inc.
―
OS Therapies Incorporated
―
Ownership Overview
31.11% Insiders
2.29% Mutual Funds
42.26% Other Institutional Investors
23.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---